Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
South Korea · Delayed Price · Currency is KRW 8,310.00
-10.00 (-0.12%)
Last updated: Jun 4, 2026, 2:19 PM KST
KRX:007570 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 275,513 | 272,422 | 268,678 | 266,669 | 247,773 | 242,511 |
Other Revenue | -0 | - | - | -0 | -0 | -0 |
| 275,513 | 272,422 | 268,678 | 266,669 | 247,773 | 242,511 | |
Revenue Growth (YoY) | 1.31% | 1.39% | 0.75% | 7.63% | 2.17% | -29.37% |
Cost of Revenue | 163,296 | 156,142 | 157,461 | 150,265 | 139,579 | 137,865 |
Gross Profit | 112,217 | 116,280 | 111,217 | 116,404 | 108,194 | 104,646 |
Selling, General & Admin | 86,020 | 82,088 | 73,907 | 73,605 | 69,591 | 69,145 |
Research & Development | 28,821 | 26,099 | 24,740 | 23,748 | 22,395 | 16,829 |
Other Operating Expenses | 2,067 | 2,024 | 1,967 | 1,954 | 1,832 | 1,764 |
Operating Expenses | 118,007 | 111,318 | 101,595 | 100,024 | 93,945 | 89,458 |
Operating Income | -5,790 | 4,963 | 9,622 | 16,379 | 14,249 | 15,188 |
Interest Expense | -2,964 | -3,031 | -2,932 | -3,225 | -2,132 | -1,894 |
Interest & Investment Income | 552.38 | 502.77 | 619.4 | 361.43 | 279.06 | 348.43 |
Earnings From Equity Investments | -1,276 | -843.99 | 2,083 | -13,425 | 10,754 | 9,236 |
Currency Exchange Gain (Loss) | 648.39 | -188.29 | 1,222 | -1,011 | -551.53 | 1,265 |
Other Non Operating Income (Expenses) | 36,254 | 11,730 | 263.21 | -928.6 | 1,288 | -2,347 |
EBT Excluding Unusual Items | 27,425 | 13,132 | 10,878 | -1,849 | 23,887 | 21,797 |
Gain (Loss) on Sale of Investments | 282.06 | - | 27.78 | 8.92 | -24.78 | - |
Gain (Loss) on Sale of Assets | 89.57 | 90.04 | -8.96 | 0.53 | 21.22 | 2.86 |
Asset Writedown | 37 | 37 | 2.15 | 40.51 | -36.82 | 263.19 |
Pretax Income | 27,834 | 13,260 | 10,899 | -1,799 | 23,846 | 22,063 |
Income Tax Expense | 7,515 | 6,127 | 1,617 | 230.97 | 4,040 | 7,311 |
Earnings From Continuing Operations | 20,318 | 7,133 | 9,282 | -2,030 | 19,806 | 14,752 |
Minority Interest in Earnings | -156.04 | -227.99 | -250.39 | -378.26 | -420.96 | -719.83 |
Net Income | 20,162 | 6,905 | 9,032 | -2,409 | 19,385 | 14,032 |
Preferred Dividends & Other Adjustments | 177.95 | 177.95 | - | -88.03 | 452.64 | - |
Net Income to Common | 19,984 | 6,727 | 9,032 | -2,321 | 18,933 | 14,032 |
Net Income Growth | 88.17% | -23.55% | - | - | 38.15% | 28.98% |
Shares Outstanding (Basic) | 18 | 18 | 18 | 18 | 18 | 18 |
Shares Outstanding (Diluted) | 18 | 18 | 18 | 18 | 18 | 18 |
Shares Change (YoY) | -6.44% | -2.63% | 2.29% | -0.59% | -0.44% | - |
EPS (Basic) | 1134.13 | 374.81 | 490.00 | -128.79 | 1044.53 | 770.78 |
EPS (Diluted) | 1134.13 | 374.81 | 490.00 | -131.00 | 1044.53 | 770.78 |
EPS Growth | 97.84% | -23.51% | - | - | 35.52% | 29.11% |
Free Cash Flow | 37,819 | 6,323 | -32,585 | 8,736 | 1,938 | 39,057 |
Free Cash Flow Per Share | 2146.27 | 352.33 | -1767.81 | 484.85 | 106.90 | 2145.40 |
Dividend Per Share | - | - | - | 150.000 | - | - |
Gross Margin | 40.73% | 42.68% | 41.39% | 43.65% | 43.67% | 43.15% |
Operating Margin | -2.10% | 1.82% | 3.58% | 6.14% | 5.75% | 6.26% |
Profit Margin | 7.25% | 2.47% | 3.36% | -0.87% | 7.64% | 5.79% |
Free Cash Flow Margin | 13.73% | 2.32% | -12.13% | 3.28% | 0.78% | 16.11% |
EBITDA | 2,534 | 13,307 | 19,446 | 28,350 | 26,016 | 26,415 |
EBITDA Margin | 0.92% | 4.88% | 7.24% | 10.63% | 10.50% | 10.89% |
D&A For EBITDA | 8,324 | 8,344 | 9,824 | 11,971 | 11,767 | 11,227 |
EBIT | -5,790 | 4,963 | 9,622 | 16,379 | 14,249 | 15,188 |
EBIT Margin | -2.10% | 1.82% | 3.58% | 6.14% | 5.75% | 6.26% |
Effective Tax Rate | 27.00% | 46.21% | 14.84% | - | 16.94% | 33.14% |
Advertising Expenses | - | 6,715 | 6,409 | 6,264 | 6,312 | 7,205 |